Eirgen Pharma 2026 Brochure
Eirgen Pharma is a research-driven pharmaceutical company based in Waterford, Ireland, specialising in the development, manufacture and supply of complex oral solid dose and softgel medicines. With particular expertise in high-potency products, Eirgen provides end-to-end solutions spanning drug development, manufacturing, packaging, stability and global commercial supply, serving customers in over 60 countries.
EIRGEN PHARMA LIMITED
-
Country/Region:Ireland
-
On CPHI since:2015
-
Certificates:3
-
Employees:100 - 249
Other Content from EIRGEN PHARMA LIMITED (3)
-
News Project Elevate: Transforming Eirgen Pharma's Digital Landscape
The implementation of Project Elevate signifies a substantial improvement in our digital infrastructure. For this transformative project, we have partnered with a manufacturing technology company, Tulip Interfaces, and an IT Solutions Provider, NNIT. This collaboration will empower our operations with workflow automation, data collection, and the delivery of real-time insights directly from our production environment.
The digitization of our batch record management is designed to yield increased operational efficiency and ensure regulatory compliance. Furthermore, the initiative underscores our commitment to maintaining the highest standards of quality throughout all stages of production.
Dan Delaney, Head of Operations at Eirgen Pharma, shared his enthusiasm for the project.
“I am very proud of the team’s dedication in bringing Project Elevate to fruition. This new EBR system will be a transformative asset for our manufacturing processes. -
Brochure Eirgen Pharma Animal Health Brochure
Discover Eirgen Pharma's Animal Health Services - from species-specific formulation expertise, to palatability & taste masking, and faster launches. -
News Facility Expansion - Launching in Q3 2025, now open for projects!
Eirgen Pharma’s new state-of-the-art facility expansion in Waterford significantly increases our capacity to support global partners. Designed for flexibility and scalability, it enables the manufacture of over 500 million oral solid dose units annually, including high-potency and non-potent products. This investment reflects our commitment to delivering science-led, high-quality pharmaceutical solutions — from clinical development to full commercial supply — all under one roof.